Free Trial
NASDAQ:TELA

TELA Bio Q2 2025 Earnings Report

TELA Bio logo
$1.72 +0.06 (+3.30%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.76 +0.04 (+2.62%)
As of 08/8/2025 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TELA Bio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.18
Beat/Miss
N/A
One Year Ago EPS
N/A

TELA Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$20.67 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

TELA Bio Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

TELA Bio Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
See More TELA Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TELA Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TELA Bio and other key companies, straight to your email.

About TELA Bio

TELA Bio (NASDAQ:TELA), a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

View TELA Bio Profile

More Earnings Resources from MarketBeat